2
Dec
2016

21st Century Cures Rolls Thru House, Price Poised to Gut Obamacare, and Bluebird Soars

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna
Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet